One-time gene edit slashes bad cholesterol by half
A single infusion of a CRISPR-Cas9 gene-editing therapy lowered LDL cholesterol by 50% in a Cleveland Clinic Phase 1 trial. Fifteen patients with lipid disorders that do not respond to standard drugs received the treatment. Within two weeks, LDL fell by half and triglycerides dropped about 55%, and the reductions persisted for at least 60 days. No serious treatment-related adverse events were reported during short-term follow-up. The findings were presented at the American Heart Association's Scientific Sessions 2025 and appeared in the New England Journal of Medicine.
Patients with stubborn high cholesterol now take a pill every day for life. One day, a single treatment might be enough.
Source: Cleveland Clinic First-In-Human Trial of CRISPR Gene-Editing Therapy Shown to Safely Lower Cholesterol and Triglycerides (newsroom.clevelandclinic.org).
Written by the HappyGood desk from the primary source linked above and checked against it. Every story links its source. Corrections: [email protected].
More from the archive
- Bringing back the American chestnut: four approaches to a forest giant's return October 14, 2026
- 5 search and rescue teams, RCMP find stranded person in canyon above Penticton October 14, 2026
- Mackenzie Macdonald, 16, heads to the Youth Olympics for Australia in taekwondo October 13, 2026
- Parksville festival volunteers help deliver record $89,270 donation October 12, 2026
- Police fetch antivenom as three Blue Mountains rescues unfold in a day October 12, 2026